natgillin/translations-raw huggingface dataset:
The compound according to anyone of claims 1 to 8 for use as a pharmaceutical composition or a medicament, wherein preferably said use is for the prophylaxis or therapy of a disorder associated with aberrant potassium channel activity in mammals, wherein preferably the disorder to be treated is an inner ear hearing loss after damage or loss of sensory hair cells in an organ of Corti. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da se upotrebljava kao farmaceutski pripravak ili lijek za profilaksu ili terapiju kod gubitka sluha unutrašnjeg uha nakog oštećenja ili gubitka osjetnih vlaknastih stanica u Cortijevom organu.
Sulphated hyaluronic acid for topical use for the treatment of clots of fibrin and thrombi which are formed at the skin level, wherein sulphated hyaluronic acid is for use in the fibrinolysis/debridement of clots and thrombi and wherein said sulphated hyaluronic acid has a sulphation degree equal to 1 or 3, intended as the number of sulfate groups per disaccharide unit, said sulphated hyaluronic acid being prepared starting from a hyaluronic acid (HA) having a molecular weight ranging from 10,000 to 50,000 Da or from 150,000 to 250,000 Da or from 500,000 to 750,000 Da, the sulphation involving the alcohol hydroxyls present in the polysaccharide (HA) chain. 
Sulfatirana hijaluronska kiselina za topikalnu primjenu za sprječavanje i/ili liječenje patoloških stanja kože povezanih s imunološkom obranom od deficijencije IL-10 odabranom od sljedećih: vitiligo, ekcem, psorijaza i dermatitis, a koja stimulira sintezu protuupalnih citokina, a rečena sulfatirana hijaluronska kiselina (HA) ima molekulsku masu u rasponu od 150000 do 250000 Da ili 500 000 do 750 000 Da, a stupanj sulfatiranja jest 1, izražen kao broj sulfatnih skupina po disaharidnoj jedinici, a sulfatacijom su obuhvaćene alkoholne hidroksilne skupine prisutne u polisaharidnom lancu.
The recombinant RSV antigen of any one of paragraphs 3-10, wherein the F2 domain comprises an RSV F protein polypeptide corresponding to amino acids 26-105 and/or wherein the F1 domain comprises an RSV F protein polypeptide corresponding to amino acids 137-516 of the reference F protein precursor polypeptide (Fo) of SEQ ID NO:2. 
Rekombinantni RSV antigen u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što domena F> sadrži RSV F proteinski polipeptid koji odgovara aminokiselinama 26-105 i/ili što domena F, sadrži RSV F proteinski polipeptid koji odgovara aminokiselinama 137-516 u referentnom F proteinskom polipeptidu preteči (Fo) sa SEQ ID NO:2.
and wherein the pH of the liquid is adjusted to about 6.5 to 7.5 and the osmolality is about 270 to 300 mOsm/Kg. 
te pri čemu je pH vrijednost tekućine namještena na 6,5 do 7,5, a osmolalnost je 280 do 300 mOsm/kg.
A heat transfer apparatus for transferring heat from a first relatively cold medium to a second relatively hot medium, the apparatus comprising: a gastight drum rotatably mounted in a frame, a first heat exchanger mounted inside the drum relatively far from an axis of rotation of the drum, where the gastight drum is configured to rotate a compressible fluid about the axis of rotation of the drum to generate a radial temperature in the fluid that increases from a section at or relatively close to the axis of rotation to a section relatively far from the axis of rotation, 
Uređaj (1) za prijenos topline iz prvog relativno hladnog medija u drugi relativno topli međij, koji sadrži bubanj nepropustan za plin rotacijski montiran u okvir, i prvi izmjenjivač topline (23) montiran unutar bubnja (6) relativno daleko od rotacione osi bubnja, naznačen time da bubanj sadrži fluid koji se može komprimirati i uređaj je predviđen za rad pod pritiskom, u fluidu, većim od 2 bara mjereno na rotacionoj osi.
Printed circuit 38 (FIG. 3 d) is then placed inside sunken seat 12 a, and is connected electrically to receiving antenna 42, transmitting antenna 44, and through connector 26 . 
Å tampani krug 38 (Slika 3d) se zatim smješta unutar upuštenog sjedišta 12a 1 električki povezuje na prijemnu antenu 42, predajnu antenu 44 i kroz konektor 26, Å tampani krug 38 se povezuje na antene 42, 44 koristeći upletene kabele koji se kroz stijenku 10 protežu na hermetički način.
obtaining of the value of at least one digital information item that is different from those obtained by entropy decoding, from the calculated value. 
- < rekonstrukcije, iz navedenog izračunatog pariteta, vrijednosti predznaka preostale stavke podatka iz podskupa.
A unit dose of 0.5ml of an aqueous pharmaceutical solution which contains in solution 20mg glatiramer acetate and 20mg mannitol. 
Jedinična doza od 0,5 ml vodene farmaceutske otopine naznačena time, da u otopini sadrži 20 mg glatiramer acetata 120 mg manitola.
wherein R, R′, R4 and R5 have the above reported meanings; and subjecting the compound of formula (4) to Smile's rearrangement in the presence of bases, so as to obtain the final compound of formula (5) 
I pri čemu R, R', Ra i Rs imaju gore navedena značenja; i (d) podvrgavanje spoja s formulom (4) Smile-ovom premještanju u prisutnosti baza, tako da se dobije konačni spoj formule (5)
In one embodiment, the improvement in an asthma-associated parameter is an increase of at least 0.10 L from baseline of FEV1. 
(a) povećanje od početne vrijednosti forsiranog izdisajnog volumena u prvoj sekundi (FEV1) od najmanje 0.10 L;
at least one heavy chain variable region, said heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:5; a CDRH2 amino acid sequence of SEQ ID NO:20; and 
najmanje jednu varijabilnu regiju teškog lanca, spomenuta varijabilna regija teškog lanca obuhvaća: CDRH1 sekvencu amino kiseline SEK ID BR: 4;CDRH2 sekvencu amino kiseline SEK ID BR: 18; iCDRH3 sekvencu amino kiseline SEK ID BR: 43;
A compound of formula (I) or a salt or solvate thereof: for use in the treatment of ocular neovascular disorders by oral administration. 
Spoj formule (1) ili njegova sol ili solvat: naznačen time što je namijenjen liječenju neovaskularnih poremećaja oka topikalnom primjenom izravno u oko.
contacting the trans-(+)-A9-tetrahydrocannabinol from step (b) with trans-(-)-A9-tetrahydrocannabinol and a non-polar organic solvent to form the first composition. 
kontaktiranje trans-(+)-A9-tetrahidrokanabinola iz koraka (b) sa trans-(-)-A9-tetrahidrokanabinolom i nepolarnim organskim otapalom tako da formiraju prvi sastav.
The reaction mixture was refluxed for 18h, then cooled and poured into water (400 mL). Aq. 
Reakcijska smjesa se ostavi uz protutok kroz 18 sati, potom ohladi i prelije u vodu (400 ml).
or a pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) has at least one functional group to which a polymeric moiety is conjugated, wherein the at least one functional group to which a polymer moiety is conjugated is selected from hydroxy, substituted or unsubstituted lower alkyl, lower alkoxy, carboxy, alcoxycarbonyl, amino, lower alkylamino, lower alkylaminocarbonyl and/or oxime group and whereby the term "lower alkyl" when used alone or in combination with other groups refers to a straight chained or branched lower alkyl group containing from 1-6 carbon atoms, the term "lower alkenyl" refers to a C2-C6 alkenyl group which may be straight chained or branched and may be in the Z or E form, the term "lower alkynyl" refers to a C2-C6-alkynyl group which may be straight chained or branched, and the term "lower alkoxy" refers to an alkoxy group containing from 1 to 6 carbon atoms. 
W' i W* su nezavisno vodik, hidroksi ili W' i W? zajedno predstavljaju kisik; ili njegova farmaceutski prihvatljiva sol, naznačen time što spoj formule (I) ima najmanje jednu funkcionalnu grupu za koju je konjugirana polimerna grupa, pri čemu je najmanje jedna funkcionalna grupa za koju je polimerna grupa konjugirana izabrana od hidroksi, supstituiranog ili nesupstituiranog nižeg alkila, nižeg alkoksi, karboksi, alkoksikarbonil, amino, nižeg alkilamino, nižeg alkilaminokarbonila i/ili oksim grupe i pri čemu termin "niži alkil" kada se koristi pojedinačno ili u kombinaciji sa drugim grupama označava ravnolančanu ili razgranatu nižu alkil grupu koja sadrži od 1-6 atoma ugljika, termin "niži alkenil" označava C2-Cg alkenil grupu koja može biti ravnolančana ili razgranata i može biti u Z ili E obliku, termin "niži alkinil" označava C>-Cg-alkinil grupu koja može biti ravnolančana ili razgranata, 1 termin "niži alkoksi" označava alkoksi grupu koja sadrži od 1 do 6 atoma ugljika.
A pharmaceutical composition according to claim 7, wherein said composition is suitable for administration to a patient by injection or infusion. 
Farmaceutski sastav prema bilo kojem zahtjevu od 11 do 26, naznačen time, da je spomenuti sastav pogodan za primjenu na pacijentu pomoću injekcije.
After evaporation, the residue was purified by column chromatography on silica gel with dichloromethane to afford ethyl (2-chloro-3-methoxyphenyl)acetate 7c (2.78 g, 94%) as a yellow oil. 
Nakon otparavanja ostatak se pročisti kromatografijom na stupcu silikagela, uz eluiranje diklormetanom kako bi se dobilo etil-(2-klor-3-metoksifemiljacetat 7e (2,78 g, 94 %) u obliku žutog ulja.
reacting cyclosporin-A (CsA) with a basic lithium alkylamide, in the presence of a suitable solvent optionally with LiCl, followed by reaction with a suitable electrophile to generate a compound of Formula 1: 
1) dovođenja u reakciju ciklosporina-A (CsA) s baznim litij alkilamidom, u prisutnosti odgovarajućeg otapala, nakon čega je uslijedila reakcija s odgovarajućim elektrofilom da bi se generirao spoj iz Formule 1:
A use according to claim 13 characterized by comprising one or more of the following steps: disconnecting the hydraulic fitting (12) from a hydraulic component associated with the hydraulic system; 
Primjena u skladu sa patentnim zahtjevom 13 naznačena time da sadrži jedan ili više sljedećih koraka: razdvajanje dijela hidraulične opreme (12) od hidraulične komponente koja je povezana sa hidrauličnim sistemom;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5-il)amid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A combination according to claim 3 wherein the PDE4 inhibitor is selected from the group comprising cilomilast, roflumilast, denbufylline and tetomilast optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. A combination according to claim 4 wherein the PDE4 inhibitor is roflumilast. A combination according to claim 4 wherein the PDE4 inhibitor is cilomilast. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je B2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)-formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
In other embodiments, the cancer is of the bladder, blood, bone, brain, breast, central nervous system, cervix, colon, endometrium, esophagus, gall bladder, genitalia, genitourinary tract, head, kidney, larynx, liver, lung, muscle tissue, neck, oral or nasal mucosa, ovary, pancreas, prostate, skin, spleen, small intestine, large intestine, stomach, testicle, or thyroid. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je rak, i rak je rak mjehura, krvi, kostiju, mozga, dojke, središnjeg živčanog sustava, grlića maternice, debelog crijeva, endometrija, jednjaka, žučnog mjehura, genitalija, genitourinarnog trakta, glave, bubrega, grkljana, jetre, pluća, mišićnog tkiva, vrata, oralne ili nosne sluznice, jajnika, gušterače, prostate, kože, slezene, tankog crijeva, debelog crijeva, želuca, testisa ili štitnjače.
An isolated human monoclonal antibody, or antigen binding portion thereof, wherein the antibody, or antigen binding portion thereof, comprises: 
Izolirano humano monoklonsko antitijelo, ili njegov dio koji veže antigen, naznačeno time da antitijelo, ili njegov dio koji veže antigen, sadrži:
In a 500 mL flask, it was dissolved 7.3 g (32.9 mmol) of 2-methylthioisosorbide 5-mononitrate (3) obtained according to Example 3 in 75 mL of dioxane. 
U tikvici od 500 mL se otopi 7,3 g (32,9 mmola) 2-metiltioizosorbid 5-mononitrata (3) dobivenog prema primjeru 3 u 75 mL dioksana.
The method according to claim 1, wherein the disease or disorder is fallopian cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak prostate.
The above-described methods may be used to advantage in a system for transmitting digital signals based on a 16QAM or 64QAM or QAM256 modulator, and particularly in an audio/video digital signal transmitter for broadcasting digital terrestrial television signals. 
Sustav u skladu s patentnim zahtjevom 3, naznačen time, da sadržava audio/video odašiljač digitalnog signala za emitiranje digitalnih zemaljskih televizijskih signala.
A pram or stroller equipped with an electric power unit between its rear wheels, a pressure sensor on the handle and a central processing unit adapted to carry out the method of claim 1 or 2. 
Dječja kolica ili kišobran kolica opremljena s električnim napajanjem između svojih zadnjih kotača, senzorom pritiska na ručki i centralnom procesorskom jedinicom prilagođenom za provođenje postupka iz patentnog zahtjeva 1 ili 2.
A construction according to claim 8 wherein the first and second concave surfaces, and the convex formation between the first and second curved surfaces, where provided, are each of a local respectively internal and external, radius of 18mm. 
Konstrukcija kotača u skladu s patentnim zahtjevom 4, naznačena time da su primarne i sekundarne konkavne površine (41, 42) i konveksna formacija (44) između primarnih i sekundarnih zakrivljenih površina (41, 42) svaka lokalnog, odnosno unutarnjeg i vanjskog polumjera od 18 mm.
The compound according to claim 10, wherein the disease accompanied by itch is allergic dermatitis or urticaria. 
Spoj u skladu s patentnim zahtjevom 10, naznačen time što je bolest praćena svrbežom alergijski dermatitis ili koprivnjača.
6 f and FIG. 6 g present blanks of the body of the box in various realizations, whereat these are blanks presented in FIG. 
5g prikazuju razne izvedbe shema tijela kutije, a to su sheme kutija prikazanih u Sl. 5 - SI. 5g.
The use of the composition of clause 33 as a medicament. The use of the composition of clause 33 for the preparation of a medicament for the prevention of a PCV2 infection. 
Uporaba sastava prema zahtjevu 29, naznačena time, da služi u proizvodnji lijeka za prevenciju infekcije s PCV2.
In a preferred embodiment the rail may be an upper rail mounted on an upper side of the barrel or a lower rail mounted on an underside of the barrel. Preferably, the rail is a bracket having rail slots on one side of the bracket and a locating fin on an opposite side of the bracket. 
Vatreno oružje u skladu s patentnim zahtjevom 1, naznačeno time što je tračnica (40, 55, 60) nosač koji ima utore za tračnicu (44) na jednoj strani nosača, a dio suprotne strane nosača ima tražilicu (45).
The antifouling paint according to claim 5, wherein the anti-microbial-adhesion agent comprises a compound selected from the group consisting of vanillin, 4-hydroxybenzaldehyde, 3,4-dihydroxybenzaldehyde, 2,5-dimethoxybenzaldehyde, 3,4-dimethoxybenzaldehyde, and any combination thereof. 
Protuobraštajni premaz prema zahtjevu 1, naznačeno time da anti-mikrobni agent prijanjanja sadrži sastav izabran među grupom koja se sastoji od vanilina, 4-hidroksibenzaldehida, 3,4-dihidroksibenzaldehida, 2,5-dimetoksibenzaldehida, 3,4-dimetoksibenzaldehida, te svake kombinacije istih.
The rodent of claim 12, wherein said humanized SIRPa protein comprises amino acid residues 28-362 of SEQ ID NO: 4. 
Glodavac u skladu s patentnim zahtjevom 12, naznačen time što navedeni humanizirani protein SIRPo. sadrži aminokiselinske ostatke 28-362 u SEQ ID NO: 4.
The compound of claim 44 wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 
Formulacija u skladu sa patentnim zahtjevom &8 gdje je interferon odabran od interferona alfa 2B, pegiliranog interferona alfa, konsenzusnog interferona, interferona alfa 2A, i limfoblastičnog interferona tau.
Compounds of claims 1 or 2, of the formula wherein, R1, R2, R3 and R4 are as above and its enantiomers, diastereomers and salts. 
, R2, R3 i R4 su definirani kao gore kao i njihovi enantiomeri, diastereomeri i soli.
from 0.05 to 2.5% by dry weight of an extract of Paullinia species, and 
- od 0,05 do 2,5% suhe mase ekstrakta Paullinia vrsta, i
The process of claim 9 in which the fluid dynamics model is code ANSYS R14.5, taking into consideration the multi-phase flow field ranging from solid batch material to liquid melt and gas generated in the course of the conversion, and the batch-to-melt conversion. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što je model dinamike fluida kod ANSYS R14.5, koji uzima u obzir višefazno polje toka u rasponu od čvrstog šaržnog materijala do tekuće taline 1 plina nastalih tijekom pretvorbe, te pretvorbu šarže u talinu.
Where the removal method is standardised and reproducible then monitoring of SDS levels during SDS removal may not be necessary, as the same result can generally be expected each time the procedure is performed (although final confirmatory measurements may be performed). 
Kada je metoda odstranjivanja standardizirana i može se reproducirati, tada opažanje razina SDS za vrijeme odstranjivanja SDS ne mora biti nužno, budući da se isti rezultat općenito može očekivati svaki puta kada se procedura izvodi (premda se konačna potvrđujuća mjerenja mogu izvesti).
According to another embodiment the predetermined parameter value is a pH value, wherein the pH value is from 5.5 to 9, preferably from 7 to 8.5. 
Postupak prema zahtjevu 19, pri čemu je predodređena vrijednost parametra pH vrijednost, gdje je pH vrijednost od 5.5 do 9, poželjno od 7 do 8.5.
Other details and features of the invention will become clear from the following description of specific embodiments of the invention, which are given by way of illustration only and are not restrictive in any respect. 
Ostale potankosti i obilježja izuma postat će jasniji iz sljedećeg opisa specifičnih varijanti koje su predmetom ovog izuma, koje se iznose za ilustraciju i nisu ograničavajuće ni na koji način.
a parser which obtains an effective coefficient flag of a sub residual block among the sub residual blocks from a bitstream, the effective coefficient flag of the sub residual block indicating whether at least one non-zero effective transformation coefficient exists in the sub residual block, and when the effective coefficient flag indicates that at least one non-zero transformation coefficient exists in the sub residual block, obtains transformation coefficients of the sub residual block based on location information of the non-zero transformation coefficient and level information of the non-zero transformation coefficient obtained from the bitstream; and 
kada zastavica kodiranog bloka označava da rezidualni blok transformacije sadrži barem jedan efektivni koeficijent transformacije koji nije nula, dobivanje koeficijenata transformacije prve jedinice frekvencijskog pojasa na temelju karte značajnosti koja ukazuje na mjesta efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa i informacije o razini efektivnih koeficijenata transformacije koji nisu nula koji postoje u prvoj jedinici frekvencijskog pojasa dobivenoj iz toka bitova; provođenje inverzne transformacije na rezidualnom bloku transformacije;
A method for preparing a hydrogen sulfate salt of Compound 1 according to any one of claims 1 to 8, said method comprising 
Postupak pripreme soli hidrogen sulfata od Spoja 1 prema bilo kojem od zahtjeva 1 do 8, taj postupak obuhvaća (1) reakciju mulja Spoja 1 u organskoj tekućini s barem stehiometrijskom količinom sulfatne kiseline i vode;
The medicine according to claim 41, wherein the disease caused by amyloid-B is Alzheimer's disease, dementia, Down's syndrome or amyloidosis. 
Lijek u skladu s patentnim zahtjevom 14, naznačen time, da je bolest prouzročena beta- amiloidom Alzheimerova bolest, demencija, Downov sindrom ili amiloidoza.
A composition according to any one of the preceding claims, wherein the filler comprises a sugar alcohol, for example mannitol. 
Sastav prema zahtjevu 2, naznačen time, da punilo sadrži manitol kao šećerni alkohol.
The 1-heterodiene derivative represented by formula (1) or salt thereof according to claim 1, wherein Q1 represents an optionally substituted C6-C10 aryl group or an optionally substituted pyridine-2-yl. 
Derivat 1-heterodiena predstavljen formulom (1) ili njegova sol prema zahtjevu 1, gdje Q1 predstavlja po izboru supstituiranu C6-C10 aril skupinu ili po izboru supstituirani piridin-2-il.
The present invention, in one aspect, proposes to add sealing material to the outer surface of the capsule. 
Predmctni izum, u jednom aspcktu, predlaže dodavanje materijala za brtvljenje na vanjskoj plohi čahure.
The layer sequence repeater module of Claim 12, wherein the cap (32, 34), distribution (36), spreader (38) and repeater (40) disks are configured and arranged to distribute a first melt stream flowing in a first direction and a second melt stream flowing in a second direction opposite the first direction. 
Modul za ponavljanje niza slojeva u skladu s patentnim zahtjevom 12, naznačen time što su pokrovni (32, 34), razdjelnički (36), razmačni (38) i ponavljački (40) diskovi tako konfigurirani i smješteni da raspodjeljuju struju prve taline koja teče u prvom smjeru 1 struju druge taline koja teče u drugom smjeru, suprotnom prvom smjeru.
The above mentioned means for adjusting the axial position with respect to the sole 2 comprise a first seat 9 provided in the sole 2 at the area of the heel 4 of the sole, starting from the upper surface 10 of the sole. 
Iznad spomenutog sredstava za podešavanje aksijalnog položaja u odnosu na potplat 2 nalazi se prvi dosjed 9, postavljen u potplatu 2, u području pete 4 potplata, koji započinje od gornje površine 10 potplata.
The liquid composition according to claim 1, wherein said sugar is selected from the list consisting of: glycerol, erythrose, erythriol, xylitol, arabitol, ribose, xylose, arabinose, glucose, tagalose, mannose, galactose, fructose, inositol, sorbitol, mannitol, galactitol, a combination of glucose and fructose, maltose, sophorose, lactose, cellobiose, melibiose, trehalose, sucrose, palatinose, maltulose, lactulose, maltitol, lactitol, raffinose, maltotriose, melezitose, cellotriose, ciritol, maltotetraose, stachyose, cellotetraose, maltopentaose, cellopentaose, maltohexaose, cellohexaose, oligosaccharides. 
Tekući pripravak u skladu s bilo kojim jedan patentnih zahtjeva 1 do 10, naznačen time što se navedeni šećer bira sa spiska koji čine: glicerol, eritroza, eritriol, ksilitol, arabitol, riboza, ksiloza, arabinoza, glukoza, tagaloza, manoza, galaktoza, fruktoza, inozitol, sorbitol, manitol, galaktitol, kombinacija glukoze i fruktoze, maltoza, soforoza, laktoza, celobioza, melibioza, trehaloza, saharoza, palatinoza, maltuloza, laktuloza, maltitol, laktitol, rafinoza, maltotrioza, melezitoza, celotrioza, ciritol, maltotetraoza, stahioza, celotetraoza, maltopentaoza, celopentaoza, maltoheksaoza, celoheksaoza, oligosaharidi,